The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.
March 31st 2025
Currently, BEAM-302 is undergoing a phase 1/2 clinical trial to evaluate its efficacy in patients with alpha-1 antitrypsin deficiency (AATD) who have lung disease and liver disease.
Counseling Patients with the Difficult Diagnosis of Hepatitis C
February 15th 2010Hepatitis C can be a challenging disease for patients. Pharmacists can be instrumental in educating their patients about the pharmacologic agents available for treatment and provide them with valuable resources to successfully manage this condition.
Read More